Dexanabinol

Drug Profile

Dexanabinol

Alternative Names: Dexanabinone; ETS-2101; HU-211; PA-50211; PRS-211007; Sinnabidol

Latest Information Update: 28 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hebrew University of Jerusalem
  • Developer e-Therapeutics; Northern Institute for Cancer Research; Pharmos Corporation; University of California, San Diego
  • Class 3-ring heterocyclic compounds; Antineoplastics; Cannabinoids; Neuroprotectants; Small molecules
  • Mechanism of Action Apoptosis stimulants; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Brain injuries
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Brain cancer; Malignant melanoma; Solid tumours
  • Discontinued Brain injuries; Glaucoma; Mild cognitive impairment; Multiple sclerosis

Most Recent Events

  • 28 May 2018 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, First-line therapy, Late-stage disease) in Germany (IV, Infusion)
  • 28 May 2018 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, First-line therapy, Late-stage disease) in Poland (IV, Infusion)
  • 28 May 2018 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, First-line therapy, Late-stage disease) in Spain (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top